Logo

Mallinckrodt Signs an Agreement with Silence Therapeutics to Develop and Commercialize RNAi Therapeutics for Complement-Mediated Diseases

Share this

Mallinckrodt Signs an Agreement with Silence Therapeutics to Develop and Commercialize RNAi Therapeutics for Complement-Mediated Diseases

Shots:

  • Silence to receive $20M up front- $10M as research milestone for SLN500 + for each of the two optioned assets- ~$663M including clinical- regulatory and commercial milestones and royalties on net sales for SLN500. Silence will also receive funds for P-I development including GMP4 manufacturing and will be responsible for all pre-clinical activities and for executing development program of each asset until the end of P-1   
  • Mallinckrodt to get exclusive WW rights for Silence’s SLN500 candidate with an option to license up to two additional pre-clinical RNAi assets and will be responsible for all clinical development and global commercialization. If the option is executed- Silence will receive up to $703M/asset for clinical- regulatory & commercial milestones on each optional asset plus royalties
  • Silence’s SLN500 is a C3-targeting RNAi therapeutic pre-clinical candidate involved in targeting specific protein in the complement pathway  

Click here to read full press release/ article | Ref: Mallinckrodt Pharmaceuticals | Image: Behnace


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions